Oncarin: A cure for the source of cancer
by ZMD GROUP
Z.M.D. Medical Ltd has set a goal to produce probiotic preparations to rehabilitate distressed colon microflora in order to eliminate cancer from patients’ immune systems and help it recover.
Colon bacteria are believed to inhibit the growth of many pathogenic bacteria and fungi. Nowadays, the world exploited this property by using Fecal Microbiota Therapy (FMT) to treat diseases caused by pathogenic bacterium Clostridium difficile. In this approach, stool from a healthy individual was transplanted to a patient, which allowed the colon bacteria from the healthy person to replace the bacteria Clostridium difficile in the patient’s intestine. This approach expands worldwide.
FMT is becoming more common and, for certain intestinal infections, has become indispensable. However, this method has two major drawbacks:
- In addition to healthy bacteria, donor feces contains various scat-toxins (stool poisons) that can harm the health of the recipient.
- No criteria exist to define a healthy donor and no method exists to determine such criteria. Donor stool may feel great and appear healthy, when in reality it may be quite the opposite. The donor may suffer from a pathology that is undetected. Even a donor with no health problems may pose a risk, and their bacteria may be diseased and therefore ineffective or even harmful to the recipient. Human stool cannot be transplanted between humans without certain knowledge of the donor’s state of health
However, controlling the strength and the order of bacteria is just one of the functions of the microflora of the large intestine. The unchanging composition of the microflora of the large intestine and its location at the end of the digestive tract give an indication of the main function of a specific part of this composition. Constructing body cells require amino acids and other organic molecules, and energy balance requires glucose (glucose burns in the presence of oxygen and releases energy). Unfortunately, these materials are rare in the environment: amino acids are found in protein molecules, and glucose is found in sugars, fats, and fiber. All of these compounds, however, are found in the tissue of living organisms (i.e., in the bodies of plants and animals).
Thus, obtaining amino acids, sugars, and the other requisite organic molecules requires capturing another living organism and consuming it. The organism is first mechanically crushed, and then the proteins, sugars, and fats are biochemically cleaved to obtain amino acids, glucose, and other organic molecules. This biochemical cleavage is part of our digestive process and uses special biochemical tools called enzymes.
However, our bodies do not have all the enzymes necessary for complete digestion of all proteins, sugars, phospholipids, fats, and fiber. The complete cleavage of these substances is an important service rendered by colonic bacteria, if not the primary service. In fact, the job of the stomach and small intestine is just to mechanically and biochemically prepare our food for the colon bacteria, which complete the digestive process by converting foodstuffs into a form that can infiltrate into the bloodstream and into the cells of the body.
This process also implies an immunological role for the colon microflora. The immune system builds the body’s cells from amino acids and other organic molecules by using the energy gained from burning glucose and oxygen. Bacteria deliver these amino acids, organic molecules, and glucose by completing the digestive process. Therefore, the health of the colon bacteria is reflected in the health of the immune system: an imbalance in the composition of the colon microflora and/or an alteration of their function (dysbacteriosis) is in fact disorders of the immune system.
The composition of colonic microflora depends strongly on the food we eat. A normal intestinal microbiota is a member of the Salmonella genus (here do not specify the bacteria species), which can cause quite a dangerous disease—salmonellosis—in humans. Birds also harbor these bacteria, although the nature of their food differs significantly from that of human food. The intestinal microflora in birds contains Escherichia coli Salmonella. Herbivores are another example: in reflecting their diet, the composition of their colonic microbiota differs from both that of birds and that of humans.
The human intestine contains about 100 trillion microorganisms, which is some tenfold more than the total number of human cells in the body. The total mass of these bacteria ranges from 1 to 3 kg depending on body mass and food supply; they make up 60% of the fecal mass. The composition of this mass of bacteria is rather clear: 99% of all bacteria come from 30 to 40 species, of which the main ones are listed below:
- Fungi (these are not bacteria)
Of the total population of the microbiota of the colon, anaerobic bacteria account for 95% to 98%, and aerobic bacteria account for about 1.5% to 2%. However, each type fulfills a specific role. Oxygen is fatal for anaerobic bacteria, whereas aerobic bacteria require oxygen for survival. Therefore, aerobic bacteria thrive near the walls of the large intestine, where a good blood supply supplies plenty of oxygen. However, very little oxygen is found in the lumen of the intestine because it is captured by the parietal aerobic bacteria. Therefore, the intestinal lumen harbors the anaerobic bacteria. Because the parietal bowel volume is much less than the lumen volume, the aerobic bacteria are far outnumbered by the anaerobic bacteria.
The composition of the intestinal microflora strongly affects the functional state of the human immune system. This is indicated by the dynamics of the oncolytic activity of bacteria of the large-intestine microflora. When this activity is drastically weakened, the patient will likely develop a growing cancer.
Why do cancerous tumors appear? One reason is beyond doubt; namely, the stress syndrome (Selye’s syndrome) with accompanying depression. This syndrome involves the release of adrenaline into the blood in the event of a threatening situation. Adrenalin leads to a reduction in the lumen of the arteries of the internal organs, which reduces their blood supply (reduced autonomic activity). In addition, blood pressure increases, which improves blood flow to the muscles (increased motor activity). As a result, the organism can move faster and thus save itself from a predator or catch its prey. After muscle stress, the adrenaline is spent, its concentration in the blood falls, and everything returns to normal. Therefore, in the wild, the Selye syndrome plays a positive role that helps organisms adapt to stressful situations.
In humans, everything happens differently because we encounter many more threatening situations than in the wild. However, these situations (e.g., threat of dismissal, family breakdown, bankruptcy, loss of position, scandals, abuse, etc.) do not require an increase in muscular capacity. Yet these situations also trigger a surge of adrenaline in the blood and a viscera spasm of arteries, resulting in hypertension (vegetative activity decreases). However, this is not followed by an increase in muscular capacity (i.e., no increase of motor activity). In other words, we do not run and physically fight the enemy. As a result, the adrenaline is not consumed.
Adrenaline thus continues to circulate in the blood even after the external threat has ceased, resulting in a visceral spasm of arteries, including the colon artery. This leads to a reduced blood supply to the colon wall, which means less oxygen and a concomitant weakening of the colonic bacterial microflora. A weakening of the bacteria, in turn, equates with a higher change of cancer and all the ensuing consequences.
Therefore, depression accompanied with stress leads to a higher probability of cancer. In today’s world, most people are under stress to varying degrees and, as a result, about 3% of the population gets cancer.
When the aerobic bacteria are weakened or even killed due to lack of oxygen because of a circulatory disorder in the colon wall, all the microflora of the large intestine suffer, because it forms a single system. The microflora actually constitutes a single body with specialized functions and their inverses.
The main conclusion from the above discussion is that a weakened colon microflora increases the probability to develop cancerous conditions and tumorous cancer growth.
This conclusion leads in fact to a second conclusion: if we replace the weakened bacteria in the intestine of the patient with normal bacteria taken from a healthy donor, the cancerous state of the immune system may be reversed which, in turn, would eliminate all cancerous tumors in the patient. (Refer above to nowadays approach in the world)
Thus, by eliminating the cancerous condition, we can eliminate cancerous tumors, which means that cancer can be cured, regardless of its type, location, and stage. To do this, we simply replace the colon bacteria with healthy bacteria. The only question is, what bacteria do we use and where do we get them?
To qualify as a donor of intestinal bacteria for a patient with any form of dysbiosis, the only criterion is that the bacteria of the intestinal microflora have a maximum oncolytic activity. Experience shows that such people may constitute less than 2% of the total population. Unfortunately, today’s microbiology industry produces probiotics from donors who are ill-suited for the role.
Z.M.D. Medical Ltd is currently dealing with this issue, which has led us to research the practical criteria to apply for determining medically suitable donors. This research has produced one patented method to determine a person’s suitability as bacterium donor, and a second patent for a mixture of aerobic bacteria that is suitable for the treatment of any disorder of the immune system, including the cancerous condition.
There are large numbers of genotypes bacteria, including many pathogenic (“enter virulent”) types. Not all strains of bacteria are suitable for use as a probiotic treatment of dysbiosis; only nonpathogenic, specially selected strains may be used. These strains are identifiable not only by their genotype, but also by their phenotype.
The various species of bacteria may have their specificity not only because of their different gene (different genotypes) but also because each genotype may have its own specific level of oncolytic activity (normal or reduced). The different functional states (e.g., based on oncolytic activity) betrays the presence of the different phenotypes of the same genotype of bacteria. The only bacteria suitable for use as probiotics are the phenotypes with the greatest oncolytic activity.
Note that the pathogenic and nonpathogenic of many strains have indistinguishable morphology. Moreover, there are no detectable differences between the phenotypes of bacteria. Therefore, selecting the proper strains for use as probiotics requires very careful phenotypic and genotypic control.
Z.M.D Medical Ltd has developed a probiotic consisting of a blend of five species of lyophilized bacteria, each of which is represented by a single phenotype with maximum oncolytic activity. To preserve the vitality of the bacteria, the drug is enclosed in a capsule that dissolves only after transiting through the stomach with its strong acid- enteric coated capsules.
The probiotic is designed to improve the functional state of the human immune system, including the elimination of cancerous conditions. Its use can prevent the functional state of the immune system from degrading to cancerous conditions, thereby preventing the patient from developing cancer (cancer prevention). The probiotic can also raise the functional state of a degraded immune system to a normal state, thereby allowing it to eliminate cancer (cancer treatment).
Of course, our product is not a panacea for all ills. The immune system is a complex system consisting of many elements, of which intestinal microflora is only the spearhead. A good therapeutic effect can be expected only in cases where the intestinal microflora is the weak link of the immune system (dysbiosis). If other parts of the immune system are degraded; they must also be treated to bring them back to a functional state.
In addition, we must eliminate the causes of dysbiosis, which include eating disorders, a variety of diseases that promote development of cancerous conditions, excessive exposure to carcinogens, etc. Most importantly, the stress and depression that comes with the Selye syndrome must be treated.
Note that, despite the complexity of the immune system and its dependence on many pathogenic factors, the use of our product will always have a positive effect. This is true not only regarding cancerous conditions, but also regarding other lesions of the immune system. Very few contraindications exist against the use of our product because it contains nothing but nonpathogenic bacteria taken from the intestines of healthy donors.
This treatment is not yet available to the public; it must still pass the cycles of clinical trials and permit phases before it can be used in clinical practice. However, the preliminary results are encouraging and give us confidence that all these cycles and phases will be successfully completed, thereby allowing the probiotic to see large-scale use.